Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Specialty drug spending growth characteristics in the U.S. 2012-2017

Specialty drug market growth characteristics in the U.S. between 2012 and 2017 (in billion U.S. dollars)

by Matej Mikulic, last edited Jul 22, 2019
Specialty drug spending growth characteristics in the U.S. 2012-2017 This statistic depicts the U.S. specialty drug market growth between 2012 and 2017. In that period, growth from specialty drugs which were for non-orphan indications amounted to an additional 82.1 billion U.S. dollars.
Show more

Specialty drug market growth characteristics in the U.S. between 2012 and 2017 (in billion U.S. dollars)

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
I think of Statista as Google for researchers. Statista provides you with the information you search for right away.
Dr. Horst Stipp

Dr. Horst Stipp
EVP, Research & Innovation, Advertising Research Foundation

Statistics on "Orphan drugs"
  • Market overview
The most important statistics
  • Companies
  • Products
  • Research and development
  • Rare diseases
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.